by Christopher Freeburn | May 21, 2013 10:45 am
On Tuesday, researchers announced that a new asthma treatment has shown dramatic effects in a mid-stage patient trial.
Dupilumab, developed by Sanofi (SNY) and Regeneron Pharmaceuticals (REGN), reduced asthma attacks by 87% in a 12-week, 104-patient study of the injectable treatment. A physician involved in the trial called the preliminary results, “the most exciting data we’ve seen in asthma in 20 years,” Reuters notes.
Designed to block proteins that lead to respiratory tissue inflammation, dupilumab has also shown promise in treating severe eczema.
Larger trials will have to be conducted before the drug can be submitted for Food and Drug Administration approval. The drug is also reported to have improved lung function in patients, reducing the need for other respiratory medicines.
Shares of Regeneron in fell more than 2% Tuesday morning trading, while Sanofi rose fractionally.
Source URL: http://investorplace.com/2013/05/new-asthma-drug-could-be-game-changer/
Short URL: http://investorplace.com/?p=350669
Copyright ©2013 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.